Delivery Order SPE2DB22D2009-SPE2DB25FM1GP
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $2,562.51 on September 18, 2025, for the supply of Emgality 300 mg (100 mg x3 syringe/mL) under a Defense Logistics Agency Medical Supply Chain contract. The award is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 19, 2025. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single task against...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pens on September 11, 2025, with a ceiling value of $1,037.40 under a firm fixed price contract type. This order represents a non-competitive set-aside delivery against AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Emgality 120 mg/ml pen injectors, valued at $3,458.00. This firm fixed-price contract, which is non-set-aside and competitively awarded, is scheduled for completion by August 7, 2025, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,088.94 to AmerisourceBergen Drug Corp for the supply of Emgality 300 mg (100 mg x 3 syringes). This firm fixed-price, non-set-aside delivery order was awarded on August 11, 2025, with an ultimate completion date of August 12, 2025. The product will be delivered to Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters and primary distribution center. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,037.40 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pens on July 30, 2025, with completion scheduled for July 31, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation. The contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen operates as a major pharmaceutical distributor and critical vendor for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the pharmaceutical product Emgality 120 mg/mL pen on May 20, 2025, with a ceiling value of $1,037.40. This firm fixed-price contract is non-competitive and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle valued through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 17, 2025, for the supply of Emgality 120 mg/ml pen injections, with a contract ceiling value of $2,810.42. This is a firm fixed-price delivery order with no set-aside designation, issued as a competitive award with an ultimate completion date of July 18, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,037.40 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pens on June 13, 2025. This contract, issued on a firm fixed-price basis with an ultimate completion date of June 16, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance and is a major pharmaceutical distributor providing critical medical supplies to...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $3,034.80 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors. This firm fixed-price, competitively awarded contract was executed on August 4, 2025, with an ultimate completion date of August 5, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. No set-aside designation was applied to this award. This...
- The Defense Logistics Agency awarded a delivery order valued at $2,334.15 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pen injectors. The award, issued on September 3, 2025, with an ultimate completion date of September 4, 2025, represents a firm fixed price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, fulfilled this requirement as a competitive award under its existing contract vehicle with the...
- SPE2DB22D2009Indefinite Delivery Contract
- SPE2DB22D2009-SPE2DB25FM1GPDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,257.28 to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Emgality 300 mg (100 mg x3 syringe/mL). This competitive award, which carries no set-aside designation, is structured as a firm fixed-price contract with an ultimate completion date of September 4, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary place of performance. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical supply vehicle extending through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies a broad portfolio of brand-name and generic medications, vaccines, and medical supplies to support military healthcare programs worldwide. Emgality, a migraine prevention medication, represents one of the specialized pharmaceutical products the contractor routinely delivers to the Defense Health Agency and other federal healthcare systems through this flexible contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.3k | 9/3/25 |